News AbbVie charts a new course for CGRPs in menstrual migraine AbbVie's Qulipta has become the first oral CGRP inhibitor to show efficacy in a phase 3 study involving women with menstrual migraine.
News FDA issues novel nods for diabetes monitor, migraine lenses In a busy week, the FDA granted two De Novo authorisations for consumer health devices and is rumoured to be mulling structural leadership changes.
News After failure in sickle cell, Fulcrum merges with Slate Following the failure of its sickle cell programme, Fulcrum Therapeutics will merge with Slate Medicines to advance Slate's migraine therapy.
News AbbVie's migraine drug cleared for migraine attacks on NHS AbbVie's Aquipta can now be commissioned by the NHS in England and Wales as an acute treatment for migraine, after a NICE decision.
News Lundbeck preps phase 3 for migraine prevention drug Lundbeck seems to have brought its migraine prevention drug bocunebart back on track with positive data for an intravenous formulation.
Digital Is DTx finally reaching drug-like efficacy? A Q&A with David... Click Therapeutics CEO David Benshoof Klein shares thoughts on what's been holding DTx back and why this could be the moment for a breakout.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.